Payment overview · 2025
General Payments
$65.16
4 reported records · 3 companies
Healthcare provider profile · identity verified
John Dorsey Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · METTER, GA · NPI 1952321937
Verified facts
What the public records show
CMS Open Payments records show John Dorsey Smith, M.D. received $65.16 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 55.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.98 | 55.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.28 | 23.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.90 | 21.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $65.16 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
119 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 554 | 77 |
| Potassium Chloride | Potassium Chloride | 439 | 100 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 423 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 321 | 98 |
| Tramadol Hcl | Tramadol Hcl | 303 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 226 | 50 |
| Furosemide | Furosemide | 226 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 52 |
| Allopurinol | Allopurinol | 203 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 188 | 40 |
| Gabapentin | Gabapentin | 147 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 26 |
| Lisinopril | Lisinopril | 132 | 36 |
| Losartan Potassium | Losartan Potassium | 131 | 36 |
| Diazepam | Diazepam | 129 | 20 |
| Clonazepam | Clonazepam | 127 | 18 |
| Metformin Hcl | Metformin Hcl | 125 | 28 |
| Pregabalin | Pregabalin | 125 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 119 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 29 |
| Famotidine | Famotidine | 110 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 24 |
| Omeprazole | Omeprazole | 110 | 23 |
| Alprazolam | Alprazolam | 109 | 15 |
| Eliquis | Apixaban | 106 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 12 |
| Mounjaro | Tirzepatide | 105 | 12 |
| Clonidine Hcl | Clonidine Hcl | 104 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 18 |
| Linzess | Linaclotide | 94 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 19 |
| Simvastatin | Simvastatin | 90 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 12 |
| Trazodone Hcl | Trazodone Hcl | 86 | 15 |
| Ondansetron Odt | Ondansetron | 85 | 23 |
| Alendronate Sodium | Alendronate Sodium | 83 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 17 |
| Lorazepam | Lorazepam | 80 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 15 |
| Carvedilol | Carvedilol | 68 | 16 |
| Temazepam | Temazepam | 68 | suppressed |
| Prednisone | Prednisone | 66 | 23 |
| Meloxicam | Meloxicam | 64 | 14 |
| Montelukast Sodium | Montelukast Sodium | 61 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 13 |
| Promethazine Hcl | Promethazine Hcl | 55 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 50 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 48 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 13 |
| Glimepiride | Glimepiride | 46 | 16 |
| Naproxen | Naproxen | 45 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 12 |
| Finasteride | Finasteride | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 32 |
| Carisoprodol | Carisoprodol | 34 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Fentanyl | Fentanyl | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 11 |
| Risperidone | Risperidone | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | 11 |
| Sucralfate | Sucralfate | 30 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 25 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Phenytoin | Phenytoin | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 16 | 12 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Olanzapine | Olanzapine | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ulticare | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $65.16 · 4 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error